1 October 2015 in The Journal of Thoracic and Cardiovascular Surgery
24 June 2022 in Journal of Cardiovascular Electrophysiology
Introduction: Atrial fibrillation (AF) is a growing health problem and is associated with increased risk of stroke. The Cox‐Maze surgical procedure has offered the highest success rate, but utilization of this technique is low due to procedure invasiveness and complexity. Advances in catheter ablation and minimally invasive surgical techniques offer new options for AF treatment.Methods: In this review, we describe current trends and outcomes of minimally invasive treatment of persistent and long‐standing persistent AF.Results: Treatment of persistent and long‐standing persistent AF can be successfully treated using a team approach combining cardiac surgery and electrophysiology procedures. With this approach, the 1‐year freedom from AF off antiarrhythmic drugs was 85%.Discussion: There are a variety of techniques and approaches used around the world as technology evolves to help develop new treatment strategies for AF. Our report will focus on a hybrid treatment approach using surgical and electrophysiology approaches providing enhanced treatment options by replicating Cox‐Maze IV lesions using skills from each specialty. Closure of the left atrial appendage as part of these procedures enhances protection from late stroke. A team approach provides a cohesive evaluation, treatment, and monitoring plan for patients. Development of successful, less invasive treatment options will help address the growing population of patients with AF.
30 March 2021 in Journal of Cardiovascular Electrophysiology
10 November 2020 in Journal of Cardiac Surgery
Objective Surgical reoperation for aortic homograft structural valve degeneration (SVD) is a high‐risk procedure. Transcatheter aortic valve replacement (TAVR) for homograft‐SVD is an alternative to reoperation, but descriptions of implantation techniques are limited. This study compares outcome in patients undergoing into two groups by the type of previously implanted aortic valve prosthesis: TAVR for failed aortic homografts (TAVR‐H) or for stented aortic bioprostheses (TAVR‐BP). Methods From 2015 to 2017, TAVR was performed in 41 patients with SVD. Thirty‐three patients in the TAVR‐BP group (six for SVD of valved conduits), and eight patients in the TAVR‐H group. The Valve Academic Research Consortium criteria were used for outcome reporting purposes. Results The patients with TAVR‐BP had predominant prosthetic stenosis (94%, p = .002), whereas TAVR‐H individuals presented mostly with regurgitation (88%, p = <.001). Patients with TAVR‐H received: Sapien‐3 (6), Sapien‐XT (1), and CoreValve (1) devices. Low, 40% ventricular fixation in relation to homograft annulus was attempted to anchor the prosthesis on the homograft suture‐line. One patient with TAVR‐BP experienced intraoperative distal prosthesis migration and Type‐B aortic dissection, and two patients in the TAVR‐H group had late postoperative proximal device migration. In both groups, there was zero 30‐day mortality, stroke, or pacemaker implantation. Conclusions TAVR for failing aortic homografts may be a feasible and safe alternative to high‐risk surgical reintervention. Precise, 40%‐ventricular device positioning appears crucial for prevention of late paravalvular leak/late prosthesis migration and minimizing the risk of repeat surgical intervention.
28 July 2022 in Journal of Cardiovascular Electrophysiology